Jennifer Knight, MD, MS, FACLP
Associate Professor, Psychiatry and Behavioral Medicine and Microbiology & Immunology
- Psychiatry and Behavioral Medicine
Dr. Knight completed her undergraduate training at the University of Wisconsin-Madison and her medical training at the Medical College of Wisconsin. She completed her residency training in a combined Internal Medicine and Psychiatry program at Rush University in Chicago, and is double board certified in both specialties. She also completed a post-doctoral research fellowship in psychoneuroimmunology at the University of Rochester Medical Center.
Dr. Knight’s research interests involve investigating the physiologic and immunologic effects that account for the relationship between psychosocial factors and clinical outcomes in hematopoietic stem cell transplant recipients. Clinically, she is the Medical Director of the Psycho-Oncology Program at Froedtert and MCW and specializes in general and psycho-oncology psychosomatic medicine consultation. She sees patients at the MCW Cancer Center and at Froedtert Hospital. She is on faculty at the Neuroscience Research Center and is also a Clinical Member of the MCW Cancer Center in the Transplantation Biology and Immunotherapy Research Program.
Mobile health (mHealth) interventions in prostate cancer survivorship: a scoping review.
(Ogunsanya ME, Sifat M, Bamidele OO, Ezenwankwo EF, Clifton S, Ton C, Knight JM, Odedina FT, Greer JA, Dwyer K, Kendzor DE.) J Cancer Surviv. 2023 Jun;17(3):557-568 PMID: 36627464 01/11/2023
Inflammatory cytokines and depression symptoms following hematopoietic cell transplantation.
(Nelson AM, Erdmann AA, Coe CL, Juckett MB, Morris K, Knight JM, Hematti P, Costanzo ES.) Brain Behav Immun. 2023 May 25;112:11-17 PMID: 37236325 05/27/2023
Fit for Duty: Lessons Learned from Outpatient and Homebound Hematopoietic Cell Transplantation to Prepare Family Caregivers for Home-Based Care.
(Applebaum AJ, Sannes T, Mitchell HR, McAndrew NS, Wiener L, Knight JM, Nelson AJ, Gray TF, Fank PM, Lahijani SC, Pozo-Kaderman C, Rueda-Lara M, Miran DM, Landau H, Amonoo HL.) Transplant Cell Ther. 2023 Mar;29(3):143-150 PMID: 36572386 PMCID: PMC9780643 SCOPUS ID: 2-s2.0-85146470226 12/27/2022
A timeline of genetic variant enrichment: from multiple myeloma diagnosis to myeloma-associated myeloid malignancy.
(Kleman A, Singavi AK, Pommert L, Mathison AJ, Hari P, Dhakal B, Mohan M, Janz S, Knight JM, Shah MV, Schinke C, Burns RT, Steinhardt GF, Rao S, Carlson KB.) Blood Adv. 2023 Feb 01 PMID: 36724511 02/02/2023
Abrupt onset of severe parkinsonism in a patient with metastatic gastrointestinal stromal tumor receiving treatment with avapritinib: A case report.
(Drom C, Schenheit K, Matzke M, Obeidat AZ, Molinaro J, Charlson J, Knight JM.) Brain Behav Immun Health. 2023 Feb;27:100570 PMID: 36578920 PMCID: PMC9791578 12/30/2022
Associations between socioeconomic status and bispecific LV20.19 CAR T-cell therapy outcomes.
(Knight JM, Hackett E, Szabo A, Wu R, Sauber G, Johnson B, Cusatis RN, Aughey E, Cole SW, Hillard CJ, Shah NN.) Haematologica. 2023 Feb 01;108(2):588-593 PMID: 36200427 PMCID: PMC9890001 SCOPUS ID: 2-s2.0-85147234722 10/07/2022
Targeting the β2 -adrenergic receptor increases chemosensitivity in multiple myeloma by induction of apoptosis and modulating cancer cell metabolism.
(Satilmis H, Verheye E, Vlummens P, Oudaert I, Vandewalle N, Fan R, Knight JM, De Beule N, Ates G, Massie A, Moreaux J, Maes A, De Bruyne E, Vanderkerken K, Menu E, Sloan EK, De Veirman K.) J Pathol. 2023 Jan;259(1):69-80 PMID: 36245401 SCOPUS ID: 2-s2.0-85143222266 10/18/2022
Biobehavioral Implications of Chimeric Antigen Receptor T-cell Therapy: Current State and Future Directions.
(Taylor MR, Steineck A, Lahijani S, Hall AG, Jim HSL, Phelan R, Knight JM.) Transplant Cell Ther. 2023 Jan;29(1):19-26 PMID: 36208728 SCOPUS ID: 2-s2.0-85143519815 10/09/2022
New-onset hallucinations with amiodarone: a case report.
(Molinaro J, DeVries P, Ha J, Knight JM.) Ann Gen Psychiatry. 2022 Aug 24;21(1):34 PMID: 36002899 PMCID: PMC9400302 SCOPUS ID: 2-s2.0-85137030748 08/25/2022
The effect of tocilizumab on patient reported outcomes and inflammatory biomarkers in hematopoietic cell transplantation.
(Taylor MR, Hillard CJ, Drobyski WR, Szabo A, Johnson BD, Zhu F, Raison CL, Cole SW, Knight JM.) Brain Behav Immun Health. 2022 Aug;23:100480 PMID: 35757656 PMCID: PMC9213229 SCOPUS ID: 2-s2.0-85133379996 06/28/2022
Biobehavioral Implications of Covid-19 for Transplantation and Cellular Therapy Recipients.
(Knight JM, Taylor MR, Rentscher KE, Henley EC, Uttley HA, Nelson AM, Turcotte LM, McAndrew NS, Amonoo HL, Mohanraj L, Kelly DL, Costanzo ES.) Front Immunol. 2022;13:877558 PMID: 35865530 PMCID: PMC9295749 SCOPUS ID: 2-s2.0-85134257906 07/23/2022
Patient-reported outcomes and neurotoxicity markers in patients treated with bispecific LV20.19 CAR T cell therapy.
(Knight JM, Szabo A, Arapi I, Wu R, Emmrich A, Hackett E, Sauber G, Yim S, Johnson B, Hari P, Schneider D, Dropulic B, Cusatis RN, Cole SW, Hillard CJ, Shah NN.) Commun Med (Lond). 2022;2(1):49 PMID: 35603278 PMCID: PMC9098435 05/24/2022